<?xml version='1.0' encoding='utf-8'?>
<document id="24023447"><sentence text="Clopidogrel and the possibility of drug-drug interaction in primary health care."><entity charOffset="0-11" id="DDI-PubMed.24023447.s1.e0" text="Clopidogrel" /></sentence><sentence text="Clopidogrel ineffectiveness is a serious problem in antiplatelet therapy"><entity charOffset="0-11" id="DDI-PubMed.24023447.s2.e0" text="Clopidogrel" /></sentence><sentence text=" Many factors may contribute to this phenomenon" /><sentence text=" One of them is clopidogrel drug-drug interaction with CYP2C19 and CYP3A4 enzyme inhibitors"><entity charOffset="16-27" id="DDI-PubMed.24023447.s4.e0" text="clopidogrel" /></sentence><sentence text=" The main goal of this descriptive study was to assess the prevalence of cases of clopidogrel-drug interactions in the primary health care physicians' practices"><entity charOffset="82-93" id="DDI-PubMed.24023447.s5.e0" text="clopidogrel" /></sentence><sentence text="" /><sentence text="During 2010-2011, 80 patients receiving clopidogrel antiplatelet therapy from primary care physicians' clinical practices were involved in this study"><entity charOffset="40-51" id="DDI-PubMed.24023447.s7.e0" text="clopidogrel" /></sentence><sentence text=" By using questionnaires and case histories, the following information was collected: Age, gender, clinical diagnoses, and medications used" /><sentence text="" /><sentence text="IN THE CURRENT STUDY, DRUGS WERE USED THAT COULD POTENTIALLY INFLUENCE THE EFFECT OF CLOPIDOGREL: Omeprazole, lipophilic statins, calcium channel blockers (CCB)"><entity charOffset="98-108" id="DDI-PubMed.24023447.s10.e0" text="Omeprazole" /><entity charOffset="130-137" id="DDI-PubMed.24023447.s10.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.24023447.s10.e0" e2="DDI-PubMed.24023447.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24023447.s10.e0" e2="DDI-PubMed.24023447.s10.e1" /></sentence><sentence text=" There was a different use of the above-mentioned drugs before and after the initiation of the clopidogrel therapy, e"><entity charOffset="95-106" id="DDI-PubMed.24023447.s11.e0" text="clopidogrel" /></sentence><sentence text="g" /><sentence text=", 12 (15" /><sentence text="0%) and 44 (55" /><sentence text="0%) patients used proton pump inhibitors (PPI) before and after the clopidogrel therapy accordingly (P = 0"><entity charOffset="68-79" id="DDI-PubMed.24023447.s15.e0" text="clopidogrel" /></sentence><sentence text="16; χ (2) = 1" /><sentence text="91)" /><sentence text=" However, pantoprazole was recommended more often than other PPI"><entity charOffset="10-22" id="DDI-PubMed.24023447.s18.e0" text="pantoprazole" /></sentence><sentence text=" The use of the potential CYP3A4 inhibitors - lipophilic statins and CCB - was increased after the prescription of clopidogrel too"><entity charOffset="115-126" id="DDI-PubMed.24023447.s19.e0" text="clopidogrel" /></sentence><sentence text=" Concomitant use of statins (mainly atorvastatin) with clopidogrel was observed in 75 (93"><entity charOffset="36-48" id="DDI-PubMed.24023447.s20.e0" text="atorvastatin" /><entity charOffset="55-66" id="DDI-PubMed.24023447.s20.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.24023447.s20.e0" e2="DDI-PubMed.24023447.s20.e0" /><pair ddi="false" e1="DDI-PubMed.24023447.s20.e0" e2="DDI-PubMed.24023447.s20.e1" /></sentence><sentence text="8%) patients and the use of CCB (mainly amlodipine) - in 33 (41"><entity charOffset="40-50" id="DDI-PubMed.24023447.s21.e0" text="amlodipine" /></sentence><sentence text="3%) patients" /><sentence text="" /><sentence text="In the primary health care practices, it is revealed that there is co-medication of clopidogrel with weak CYP3A4 inhibitors, such as lipophilic statins and amlodipine, and with the moderate CYP2C19 inhibitor - omeprazole"><entity charOffset="84-95" id="DDI-PubMed.24023447.s24.e0" text="clopidogrel" /><entity charOffset="156-166" id="DDI-PubMed.24023447.s24.e1" text="amlodipine" /><pair ddi="false" e1="DDI-PubMed.24023447.s24.e0" e2="DDI-PubMed.24023447.s24.e0" /><pair ddi="false" e1="DDI-PubMed.24023447.s24.e0" e2="DDI-PubMed.24023447.s24.e1" /></sentence><sentence text=" The latter co-medication is potentially harmful and it is very important to inform the first care professionals about the opportunity to change omeprazole to pantoprazole, which does not influence clopidogrel biotransformation"><entity charOffset="145-155" id="DDI-PubMed.24023447.s25.e0" text="omeprazole" /><entity charOffset="159-171" id="DDI-PubMed.24023447.s25.e1" text="pantoprazole" /><entity charOffset="198-209" id="DDI-PubMed.24023447.s25.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.24023447.s25.e0" e2="DDI-PubMed.24023447.s25.e0" /><pair ddi="false" e1="DDI-PubMed.24023447.s25.e0" e2="DDI-PubMed.24023447.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24023447.s25.e0" e2="DDI-PubMed.24023447.s25.e2" /><pair ddi="false" e1="DDI-PubMed.24023447.s25.e1" e2="DDI-PubMed.24023447.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24023447.s25.e1" e2="DDI-PubMed.24023447.s25.e2" /></sentence><sentence text="" /></document>